Atopic Dermatitis

The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.

Researchers of a recent systematic review and meta-analysis examine how dupilumab compares to older systemic treatments for atopic dermatitis, including methotrexate, cyclosporine and azathioprine.

The U.S. Food and Drug Administration has approved a single-dose 300 mg pre-filled pen version of dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in U.S. patients 12 years and older.

A recent study shows no increased risk of incidence of malignancies in patients using topical tacrolimus. A black box warning on the therapy has made it challenging for physicians to prescribe, and researchers hope this evidence will lead to the FDA reconsidering that warning.

Gusacitinib, an investigational oral Janus kinase/spleen tyrosine kinase inhibitor, demonstrated statistical superiority compared with placebo for improving chronic hand eczema in a phase 2b study.

Jonathan H. Zippin, M.D., Ph.D., explains what existing drugs and investigational compounds that inhibit the JAK-STAT pathway are being investigated as treatment for atopic dermatitis, alopecia areata, vitiligo and psoriasis.

LEO Pharma will soon begin marketing its monoclonal antibody tralokinumab for atopic dermatitis with the announcement that the EMA has accepted the marketing authorization application for the drug.

Full results from the second of two trials investigating the JAK1 inhibitor abrocitinib as a monotherapy for treatment of moderate-to-severe atopic dermatitis demonstrate statistical superiority of both doses compared to placebo.

The U.S. FDA has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis in children 6-11 years, making it the first biologic approved for atopic dermatitis in this particular age group.

In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.

Ruxolitinib met primary and secondary endpoints in the phase 3 TRueE-AD1 and TRuE-AD2 studies, underscoring the idea that the disruption of multiple cytokine networks simultaneously is a promising treatment approach.

Researchers evaluating several itch assessment tools say there is a need for a better way. Studies comparing the validity and reliability of itch measurement scales are lacking, say researchers who examined several available assessment tools.

Jonathan Silverberg, M.D., Ph.D., MPH, discusses criteria to keep in mind when evaluating a patient with possible atopic dermatitis.

This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.

Dermavant announces the enrollment completion for their two phase 3 clinical trials investigating the topical therapeutic aryl hydrocarbon receptor (TAMA) tapinarof as a treatment for adult plaque psoriasis, with results from the study still expected in the second half of 2020 despite the current pandemic.

The high-affinity interleukin 13 inhibitor lebrikizumab significantly improved atopic dermatitis manifestations and symptoms with a safety profile similar to placebo, according to results from a phase 2b randomized clinical trial.

A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.

LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.

Pfizer announces top-line results from its third phase 3 clinical trial investigating abrocitinib in adults with moderate-to-severe atopic dermatitis.

Thanks to the phase 3 study that led to dupilumab's approval in adolescent atopic dermatitis (AD), patients can now avoid off-label treatments that may pose a risk of significant long-term toxicity.

Researchers of a recent paper highlight advice physicians can give atopic dermatitis patients to improve their sleep and quality of life.

Gladskin announces the launch of its over-the-counter eczema topical in the U.S, which features the company’s patented Micreobalance technology.

Adult patients with moderate-to-severe atopic dermatitis who were treated with systemic agents, including cyclosporine, azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, reported a high level of disease-related burden despite those treatments, says a recent study.

Atopic dermatitis therapy is currently undergoing a revolution that promises to treat patients of all ages who are suffering from every aspect of the disease-from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression.

It’s an exciting time for atopic dermatitis patients as many new treatment options are on the market and in the pipeline. But treatment doesn’t yet offer a cure and many patients continue to suffer with symptoms, including itch, psychosocial and quality-of-life issues, according to a recent paper.

Abnormalities in epidermal barrier integrity, affecting factors such as epidermal calcium gradients, filaggrin, cornified envelopes, desquamation of corneodesmosomes and skin lipids, may also influence epidermal barrier dysfunction, according to a recent review.

A recent chart review found that eczematous eruptions occurred in 5.8% of patients using interleukin (IL)-17 inhibitors for psoriasis. Its authors believe that additional research could help identify which patients may be most at risk.

A phase 2 study shows that the oral Janus kinase (JAK) 1 inhibitor abrocitinib quickly improved atopic dermatitis (AD) severity and symptoms versus placebo with some measures achieving statistically significant separation in days.